Drugs / tumor-specific TCR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03891706 | Jan 2019 → Oct 2025 overdue | cancer | Guangzhou FineImmune Biotechnology Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tumor-specific TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03891706 ↗ |
| Modality | Cell therapy | “these TCR-T cells will be multiplied, or grown, in the laboratory” NCT03891706 ↗ |
| Route | Intravenous | “TCR-T cells will be infused intravenously (IV) over 1 hour” NCT03891706 ↗ |